China Contract Research Organization (CRO) Industry Report, 2012-2013

Feb. 2013
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES
The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

STUDY GOAL AND OBJECTIVES
This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES
◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
◆ To complement the organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
◆ To help company to succeed in a competitive market, and
Abstract

Compared to Europe and America, China developed pharmaceutical CRO industry 40 years later, with domestic industrial players amounting to over 500, most of which are SMEs. In general, Chinese CRO market scale occupies only 7%-10% of the world’s total, and in 2011-2012 the CRO market size of China approximated RMB22-28 billion.

Considering huge potentials of Chinese pharmaceutical market, intensive talent resource, relatively low cost and rich spectrum of diseases, foreign enterprises are accelerating to expand CRO market there. Presently, world-renowned CRO companies including Quintiles, Covance, PPD, CRL and ICON have set foot in China by building new establishments and M&As. In China, homegrown leaders cover WuXi AppTec Co., Ltd., Shanghai-headquartered ShangPharma Corporation, and Hangzhou Tigermed Consulting, with the respective revenue in Jan.-Sep., 2012 hitting USD374 million, USD94.47 million and USD29.84 million, the combined proportion of 14% in China CRO market.

In an aim to realize resource sharing and improve overall competitiveness, some domestic pharmaceutical CRO enterprises seek joint development by setting up alliance. A case in point is ABO, which was established in 2005 merging nine research institutes including Academy of Military Medical Sciences, National Institutes for Food and Drug Control, and National Center of Biomedical Analysis, gathering three national engineering centers and seven national engineering technology centers, with sharable hi-tech resources valuing RMB1 billion. In 2012, ABO had 38 corporate members (including Sino Biological Inc. and Pharmaron), with the total area newly increasing by 40,000 sq meters to 270,000 sq meters or more and the total revenue growing by 28.6% year-on-year to over RMB1.8 billion which accounted for 6.4% in Beijing biomedical R&D service industry. And the revenue generated by international orders rose by 14.7% YoY to RMB780 million.

In Jan. 2013, JOINN Laboratories (Beijing), a member of ABO, took over the San Francisco-based R&D and production bases of Bayer, opening a new chapter for Chinese biomedical enterprises’ acquisition of worldwide R&D bases transnational businesses in overseas countries. And JOINN Laboratories is scheduled to lavish USD100 million to set up a 300-mu（1mu=666.7sq meters）US-based Join Innovation Park, in an attempt to provide business incubator, technical support, international cooperation and other services for small-and medium-sized biomedical innovative enterprises in Silicon Valley and China.
The report highlights the followings:

- international market, domestic macro-environment and polices, laws and regulations of China CRO industry;

- status quo, market scale, competition pattern and development prediction of China CRO industry;

- Operation, CRO business and development dynamics in China of six foreign and five domestic industrial players.
1. Overview of CRO Industry
   1.1 Definition & Classification
   1.2 Industry Background

2. Development Environment of CRO Industry in China
   2.1 International Environment
   2.2 Industry Environment
   2.3 Policy Environment

3. Market Analysis of CRO Industry in China
   3.1 Status Quo
   3.2 Market Size
   3.3 Competition Pattern
   3.4 Regional Market
     3.4.1 Beijing
     3.4.2 Shanghai
     3.4.3 Chengdu
   3.5 Prospects

4. Key CRO Enterprises Worldwide
   4.1 Covance Inc.
     4.1.1 Profile
     4.1.2 Operation
     4.1.3 Revenue Structure
     4.1.4 Business in China
   4.2 PAREXEL International
     4.2.1 Profile
     4.2.2 Operation
     4.2.3 Revenue Structure
     4.2.4 Business in China
   4.3 PPD
     4.3.1 Profile
     4.3.2 Operation
     4.3.3 Business in China
     4.4 Quintiles Transnational Corp.
     4.4.1 Profile
     4.4.2 Business in China
   4.4 Quintiles Transnational Corp.
     4.4.1 Profile
     4.4.2 Business in China
   4.5 Charles River Laboratories International, Inc.
     4.5.1 Profile
     4.5.2 Operation
     4.5.3 Revenue Structure
     4.5.4 Business in China
   4.6 Asymchem Inc.
     4.6.1 Profile
     4.6.2 Business in China

5. Key CRO Enterprises in China
   5.1 WuXi AppTec Co., Ltd.
     5.1.1 Profile
     5.1.2 Operation
     5.1.3 Revenue Structure
     5.1.4 Development Trend and Prospects
   5.2 ShangPharma Corporation
     5.2.1 Profile
     5.2.2 Operation
     5.2.3 Revenue Structure
     5.2.4 Development Trend and Prospects
   5.3 Venturepharm Laboratories Ltd.
     5.3.1 Profile
     5.3.2 Operation
     5.3.3 Revenue Structure
     5.3.4 Development Trend and Prospects
   5.4 Tigermed Consulting Co., Ltd
     5.4.1 Profile
     5.4.2 Operation
     5.4.3 Revenue Structure
     5.4.4 Gross Margin
     5.4.5 Clients and Suppliers
     5.4.6 Development Trend and Prospects
   5.5 Sundia MediTech Co., Ltd.
• Classification of CRO
• Global CRO Market Size and Growth Rate, 2007-2012
• Global Key CRO Organizations and Their Business
• Total Industrial Sales and Growth Rate of China’s Pharmaceutical Manufacturing, 2008-2012
• Total Industrial Sales of China’s Bio-chemical Pharmaceutical Manufacturing, 2008-2012
• Chinese CRO Market Size and Growth Rate, 2007-2012
• Classification of Chinese CRO Companies (by Business)
• Key M&A Cases of CRO Industry in China, 2007-2011
• Regional Distribution of Leading Foreign CROs in China
• Revenue and YoY Growth Rate of ABO, 2010-2012
• Sponsors of CRO in Zhongguancun (Listed in No Particular Order)
• Platform Edge of Shanghai Pharma Engine
• Major CRO Enterprises of Shanghai Pharma Engine
• Revenue and Operating Profit of Covance, 2009-2012
• Revenue of Covance by Business, 2010-2012
• Revenue and Operating Profit of PAREXEL, 2009-2012
• Revenue of PAREXEL by Business, 2009-2012
• Revenue of PAREXEL by Region Worldwide, 2009-2012
• Revenue of PPD, 2007-2010
• Corporate Advantages of Excel PharmaStudies, Inc.
• Revenue and Operating Profit of CRL, 2009-2012
• Revenue Breakdown of CRL by Business, 2009-2012
• Asymchem Inc’s Companies and Main Businesses in China
• Branch Distribution of WuXi AppTec Co., Ltd
• Revenue and Gross Margin of WuXi AppTec Co., Ltd, 2008-2012
• Main Businesses of WuXi AppTec Co., Ltd
• Revenue of WuXi AppTec Co., Ltd by Business, 2010-2012
• Big Events of WuXi AppTec Co., Ltd, 2011-2012
• Revenue and Gross Margin of WuXi AppTec Co., Ltd, 2011-2015E
• Distribution of Subsidiaries of ShangPharma Corporation
• Four R&D Bases of ShangPharma Corporation
• Revenue and Gross Profit of ShangPharma Corporation, 2008-2012
• Revenue Breakdown of ShangPharma Corporation by Business, 2009-2011
• Shareholding (Joint-stock) Companies of Venturepharm Laboratories Ltd
• Revenue and Gross Profit of Venturepharm Laboratories Ltd, 2007-2011
• Revenue of Venturepharm Laboratories Ltd by Business, 2010-2011
• Number of Cases of Venturepharm laboratories Approved by SFDA, 2002-2011
• Seven Subsidiaries and Business Distribution of Tigermed Consulting Co., Ltd
• Domestic and Foreign Customer Distribution of Tigermed by Region
• Revenue and Profit of Tigermed, 2009-2012
• New Contract Value and Average Contract Value of New Contracts of Tigermed, 2009-2011
• New Contract Number and Value of Tigermed by Business, 2009-2011
• Operating Revenue and Operating Cost of Tigermed by Business, 2009-2011
• Revenue Breakdown of Tigermed by Region, 2009-2011
• Revenue and Proportion from Clinical Test Technical Service Business of Tigermed, 2009-2011
• Consolidated Gross Margin of Tigermed, 2009-2011
• Gross Margin of Tigermed by Business, 2009-2011
• Name List and Revenue Contribution of Tigermed’s Top 5 Clients, 2009-2011
• Name list and Procurement of Tigermed’s Top 5 Suppliers, 2011
• Number of Clinical Research Projects of Tigermed by Business
• Clinical Research Projects of Tigermed by Disease
• IPO Investment Projects of Tigermed
• Business Layout of Tigermed after Production of Fundraising Projects
You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/ 82601561

Choose type of format

PDF (Single user license) …………1,750 USD
Hard copy ……………………………1,850 USD
PDF (Enterprisewide license)………. 2,700 USD

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via PayPal.

Party A:
Name: 
Address: 
Contact Person: 
Tel: 
E-mail: 
Fax: 

Party B:
Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)
Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Contact Person: Liao Yan
Phone: 86-10-82600828
E-mail: report@researchinchina.com
Fax: 86-10-82601570

Bank details:
Beneficial Name: Beijing Waterwood Technologies Co., Ltd
Bank Name: Bank of Communications, Beijing Branch
Bank Address: NO.1 jinxiyuan shijicheng,landianchang,Haidian District,Beijing
Bank Account No #: 110060668012015061217
Routing No #: 332906
Bank SWIFT Code: COMMCNSHBJG